All Stories

  1. Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: “SLC-Phenotyping” Using Primary Human Hepatocytes

    Article • Journal of Pharmacology and Experimental Therapeutics, April 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  2. Organic Anion Transporter 2–Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability–Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs

    Article • Journal of Pharmacology and Experimental Therapeutics, August 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  3. Simultaneous Assessment of Transporter-Mediated Drug–Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey

    Article • Drug Metabolism and Disposition, June 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  4. Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System

    Article • Drug Metabolism and Disposition, March 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  5. Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation

    Article • Drug Metabolism and Disposition, February 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  6. Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  7. Molecular properties associated with transporter-mediated drug disposition

    Article • Advanced Drug Delivery Reviews, May 2017, Elsevier

    Manthena Varma, Yurong Lai

  8. Transporter-Mediated Disposition, Clinical Pharmacokinetics and Cholestatic Potential of Glyburide and Its Primary Active Metabolites

    Article • Drug Metabolism and Disposition, April 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  9. Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides

    Article • Drug Metabolism and Disposition, April 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  10. Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro–In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs

    Article • Journal of Pharmaceutical Sciences, April 2017, Elsevier

    Manthena Varma

  11. Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes

    Article • The AAPS Journal, February 2017, American Association of Pharmaceutical Scientists (AAPS)

    Manthena Varma

  12. Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach

    Article • Drug Metabolism and Disposition, February 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  13. IVIVE of drug transporters and addressing challenges

    Article • Drug Metabolism and Pharmacokinetics, January 2017, Elsevier

    Manthena Varma

  14. Unbound tissue exposure (Kpuu) of oatps substrates in the cynomolgus monkey

    Article • Drug Metabolism and Pharmacokinetics, January 2017, Elsevier

    Manthena Varma

  15. Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

    Article • Pharmaceutical Research, September 2016, Springer Science + Business Media

    Manthena Varma

  16. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions

    Article • The Journal of Clinical Pharmacology, July 2016, Wiley

    Manthena Varma

  17. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models

    Article • The Journal of Clinical Pharmacology, July 2016, Wiley

    Manthena Varma

  18. Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide

    Article • Molecular Pharmaceutics, November 2015, American Chemical Society (ACS)

    Manthena Varma, Yurong Lai

  19. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)

    Article • Pharmaceutical Research, July 2015, Springer Science + Business Media

    Manthena Varma

  20. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide

    Article • Drug Metabolism and Disposition, May 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Manthena Varma

  21. Dealing with the complex drug-drug interactions: Towards mechanistic models

    Article • Biopharmaceutics & Drug Disposition, February 2015, Wiley

    Manthena Varma

  22. Transporters in Drug Discovery

    Article • August 2014, Wiley

    Manthena Varma, Yurong Lai

  23. Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved

    Article • Clinical Pharmacokinetics, July 2014, Springer Science + Business Media

    Manthena Varma

  24. In vitroandin vivoapproaches to characterize transporter-mediated disposition in drug discovery

    Article • Expert Opinion on Drug Discovery, May 2014, Informa Healthcare

    Manthena Varma

  25. Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models

    Article • Journal of Medicinal Chemistry, May 2014, American Chemical Society (ACS)

    Manthena Varma

  26. Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide

    Article • The AAPS Journal, May 2014, American Association of Pharmaceutical Scientists (AAPS)

    Manthena Varma

  27. Quantitative Prediction of Renal Transporter-Mediated Clinical Drug–Drug Interactions

    Article • Molecular Pharmaceutics, November 2013, American Chemical Society (ACS)

    Manthena Varma

  28. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin

    Article • Biopharmaceutics & Drug Disposition, October 2013, Wiley

    Manthena Varma, Yurong Lai

  29. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs

    Article • Journal of Controlled Release, July 2013, Elsevier

    Manthena Varma

  30. Intestinal Targeting of Drugs: Rational Design Approaches and Challenges

    Article • Current Topics in Medicinal Chemistry, May 2013, Bentham Science Publishers

    Manthena Varma

  31. High Specificity in Response of the Sodium-Dependent Multivitamin Transporter to Derivatives of Pantothenic Acid

    Article • Current Topics in Medicinal Chemistry, May 2013, Bentham Science Publishers

    Manthena Varma

  32. Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

    Article • Pharmaceutical Research, March 2013, Springer Science + Business Media

    Manthena Varma, Yurong Lai

  33. Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond

    Article • Expert Opinion on Drug Metabolism & Toxicology, January 2013, Informa Healthcare

    Manthena Varma, Yurong Lai

  34. Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

    Article • Pharmaceutical Research, January 2013, Springer Science + Business Media

    Manthena Varma, Yurong Lai

  35. Pharmacokinetics and Toxicokinetics in Drug Discovery and Development

    Article • October 2012, Wiley

    Manthena Varma

  36. Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

    Article • Pharmaceutical Research, May 2012, Springer Science + Business Media

    Manthena Varma, Yurong Lai

  37. Preclinical Pharmacokinetics: Industrial Perspective

    Article • May 2012, Wiley

    Manthena Varma

  38. pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery

    Article • Molecular Pharmaceutics, May 2012, American Chemical Society (ACS)

    Manthena Varma

  39. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

    Article • Expert Opinion on Drug Metabolism & Toxicology, April 2012, Informa Healthcare

    Manthena Varma, Yurong Lai

  40. Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability

    Article • February 2012, IntechOpen

    Manthena Varma

  41. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance

    Article • MedChemComm, January 2012, Royal Society of Chemistry

    Manthena Varma

  42. Development of a new permeability assay using low‐efflux MDCKII cells

    Article • Journal of Pharmaceutical Sciences, November 2011, Elsevier

    Manthena Varma, Yurong Lai

  43. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration

    Article • Xenobiotica, October 2011, Taylor & Francis

    Manthena Varma

  44. pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1

    Article • Molecular Pharmaceutics, August 2011, American Chemical Society (ACS)

    Manthena Varma

  45. Targeting Intestinal Transporters for Optimizing Oral Drug Absorption

    Article • Current Drug Metabolism, November 2010, Bentham Science Publishers

    Manthena Varma

  46. Editorial [Hot topic: Role of Intestinal Transporters and Metabolism in the Oral Absorption of Drugs and Prodrugs (Guest Editor: Manthena V. Varma)]

    Article • Current Drug Metabolism, November 2010, Bentham Science Publishers

    Manthena Varma

  47. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state

    Article • Expert Opinion on Drug Metabolism & Toxicology, May 2010, Informa Healthcare

    Manthena Varma

  48. The Intestinal Absorption of a Prodrug of the mGlu2/3 Receptor Agonist LY354740 is Mediated by PEPT1: In Situ Rat Intestinal Perfusion Studies

    Article • Journal of Pharmaceutical Sciences, March 2010, Elsevier

    Manthena Varma

  49. Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

    Article • Journal of Medicinal Chemistry, February 2010, American Chemical Society (ACS)

    Manthena Varma

  50. Physicochemical Determinants of Human Renal Clearance

    Article • Journal of Medicinal Chemistry, August 2009, American Chemical Society (ACS)

    Manthena Varma

  51. In Vivo Dissolution: Predominant Factor Affecting the Bioavailability of Rifampicin in its Solid Oral Dosage Forms

    Article • Clinical Research and Regulatory Affairs, January 2008, Taylor & Francis

    Manthena Varma

  52. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery

    Article • Current Opinion in Chemical Biology, August 2006, Elsevier

    Manthena Varma

  53. Feasibility studies on division of fixed dose combinations of anti-tubercular drugs: an improvement in the tuberculosis therapy

    Article • Journal of Clinical Pharmacy and Therapeutics, April 2006, Wiley

    Dr Sateesh Kandavilli, Manthena Varma

  54. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: Kinetic analysis of quinidine efflux in situ

    Article • Journal of Pharmaceutical Sciences, December 2005, Elsevier

    Manthena Varma

  55. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies

    Article • Il Farmaco, November 2005, Elsevier

    Manthena Varma

  56. Relationship between lipophilicity of BCS class III and IV drugs and the functional activity of peroral absorption enhancers

    Article • Il Farmaco, November 2005, Elsevier

    Manthena Varma

  57. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers

    Article • Il Farmaco, November 2005, Elsevier

    Manthena Varma

  58. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability

    Article • Journal of Pharmaceutical Sciences, August 2005, Elsevier

    Manthena Varma

  59. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo

    Article • European Journal of Pharmaceutical Sciences, July 2005, Elsevier

    Manthena Varma

  60. Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices

    Article • Journal of Controlled Release, March 2005, Elsevier

    Manthena Varma

  61. Functional Role of P-Glycoprotein in Limiting Intestinal Absorption of Drugs:  Contribution of Passive Permeability to P-Glycoprotein Mediated Efflux Transport

    Article • Molecular Pharmaceutics, February 2005, American Chemical Society (ACS)

    Dr Sateesh Kandavilli, Manthena Varma

  62. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs

    Article • Journal of Chromatography B, February 2005, Elsevier

    Manthena Varma

  63. Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations

    Article • Journal of Pharmaceutical and Biomedical Analysis, November 2004, Elsevier

    Manthena Varma

  64. Biopharmaceutic Classification System: A Scientific Framework for Pharmacokinetic Optimization in Drug Research

    Article • Current Drug Metabolism, October 2004, Bentham Science Publishers

    Dr Sateesh Kandavilli, Manthena Varma

  65. RP-HPLC method and its validation for the determination of naloxone from a novel transdermal formulation

    Article • Il Farmaco, October 2004, Elsevier

    Dr Sateesh Kandavilli, Manthena Varma

  66. Factors Affecting Mechanism and Kinetics of Drug Release from Matrix-Based Oral Controlled Drug Delivery Systems

    Article • American Journal of Drug Delivery, January 2004, Springer Science + Business Media

    Manthena Varma

  67. Chapter 9. Mechanistic Modelling to Predict Transporter-mediated Drug Disposition and Drug–Drug Interactions

    Article • Royal Society of Chemistry

    Manthena Varma